GB201417803D0 - T cell receptors - Google Patents

T cell receptors

Info

Publication number
GB201417803D0
GB201417803D0 GBGB1417803.2A GB201417803A GB201417803D0 GB 201417803 D0 GB201417803 D0 GB 201417803D0 GB 201417803 A GB201417803 A GB 201417803A GB 201417803 D0 GB201417803 D0 GB 201417803D0
Authority
GB
United Kingdom
Prior art keywords
cell receptors
receptors
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417803.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptimmune Ltd
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Priority to GBGB1417803.2A priority Critical patent/GB201417803D0/en
Publication of GB201417803D0 publication Critical patent/GB201417803D0/en
Priority to EP15782040.8A priority patent/EP3204409A1/en
Priority to MX2017004559A priority patent/MX2017004559A/es
Priority to AU2015329783A priority patent/AU2015329783A1/en
Priority to JP2017519573A priority patent/JP6751391B2/ja
Priority to BR112017007202-5A priority patent/BR112017007202A2/pt
Priority to SG11201701983WA priority patent/SG11201701983WA/en
Priority to PCT/GB2015/052938 priority patent/WO2016055785A1/en
Priority to KR1020177012435A priority patent/KR20170092535A/ko
Priority to CA2963332A priority patent/CA2963332A1/en
Priority to NZ731571A priority patent/NZ731571A/en
Priority to CN201580054549.1A priority patent/CN107001443A/zh
Priority to RU2017115932A priority patent/RU2017115932A/ru
Priority to ZA2017/01823A priority patent/ZA201701823B/en
Priority to IL251524A priority patent/IL251524B/en
Priority to US15/480,103 priority patent/US11203627B2/en
Priority to JP2020070831A priority patent/JP2020127406A/ja
Priority to AU2020203201A priority patent/AU2020203201A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1417803.2A 2014-10-08 2014-10-08 T cell receptors Ceased GB201417803D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1417803.2A GB201417803D0 (en) 2014-10-08 2014-10-08 T cell receptors
RU2017115932A RU2017115932A (ru) 2014-10-08 2015-10-08 T-клеточные рецепторы
KR1020177012435A KR20170092535A (ko) 2014-10-08 2015-10-08 T 세포 수용체
NZ731571A NZ731571A (en) 2014-10-08 2015-10-08 T cell receptors
AU2015329783A AU2015329783A1 (en) 2014-10-08 2015-10-08 T cell receptors
JP2017519573A JP6751391B2 (ja) 2014-10-08 2015-10-08 Ｔ細胞受容体
BR112017007202-5A BR112017007202A2 (pt) 2014-10-08 2015-10-08 receptores de célula t
SG11201701983WA SG11201701983WA (en) 2014-10-08 2015-10-08 T cell receptors
PCT/GB2015/052938 WO2016055785A1 (en) 2014-10-08 2015-10-08 T cell receptors
EP15782040.8A EP3204409A1 (en) 2014-10-08 2015-10-08 T cell receptors
CA2963332A CA2963332A1 (en) 2014-10-08 2015-10-08 T cell receptors
MX2017004559A MX2017004559A (es) 2014-10-08 2015-10-08 Receptores de celulas t.
CN201580054549.1A CN107001443A (zh) 2014-10-08 2015-10-08 T细胞受体
ZA2017/01823A ZA201701823B (en) 2014-10-08 2017-03-14 T cell receptors
IL251524A IL251524B (en) 2014-10-08 2017-04-03 T cell receptors
US15/480,103 US11203627B2 (en) 2014-10-08 2017-04-05 T cell receptors
JP2020070831A JP2020127406A (ja) 2014-10-08 2020-04-10 Ｔ細胞受容体
AU2020203201A AU2020203201A1 (en) 2014-10-08 2020-05-15 T cell receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417803.2A GB201417803D0 (en) 2014-10-08 2014-10-08 T cell receptors

Publications (1)

Publication Number Publication Date
GB201417803D0 true GB201417803D0 (en) 2014-11-19

Family

ID=51947049

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417803.2A Ceased GB201417803D0 (en) 2014-10-08 2014-10-08 T cell receptors

Country Status (16)

Country Link
US (1) US11203627B2 (enExample)
EP (1) EP3204409A1 (enExample)
JP (2) JP6751391B2 (enExample)
KR (1) KR20170092535A (enExample)
CN (1) CN107001443A (enExample)
AU (2) AU2015329783A1 (enExample)
BR (1) BR112017007202A2 (enExample)
CA (1) CA2963332A1 (enExample)
GB (1) GB201417803D0 (enExample)
IL (1) IL251524B (enExample)
MX (1) MX2017004559A (enExample)
NZ (1) NZ731571A (enExample)
RU (1) RU2017115932A (enExample)
SG (1) SG11201701983WA (enExample)
WO (1) WO2016055785A1 (enExample)
ZA (1) ZA201701823B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
HUE056433T2 (hu) 2016-04-08 2022-02-28 Adaptimmune Ltd T-sejt receptorok
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
PH12020550112A1 (en) * 2017-09-22 2020-10-26 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
JP7589047B2 (ja) * 2018-04-05 2024-11-25 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
JP7261307B2 (ja) * 2019-01-28 2023-04-19 ウーシー バイオロジクス アイルランド リミテッド 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
CN114375303B (zh) * 2019-07-09 2025-04-22 基因医疗免疫疗法有限责任公司 Magea10特异性t细胞受体及其用途
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
CN114057864B (zh) * 2020-07-30 2023-12-15 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力tcr
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
MX2023007519A (es) * 2020-12-22 2023-08-03 Amgen Inc Receptores de celulas t especificos de mage-b2.
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415A1 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
JP2007032255A (ja) 2005-06-24 2007-02-08 Tokai Rika Co Ltd 車両用信号発信装置
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
WO2012013913A1 (en) 2010-07-28 2012-02-02 Immunocore Ltd T cell receptors
EP3213765B1 (en) * 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
WO2012091563A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
SI3392270T1 (sl) * 2011-09-15 2020-12-31 The United States Of America, As Represented By The Secretary Department Of Health And Human Services T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni MAGE
WO2013057586A1 (en) * 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
HK1212237A1 (en) * 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
HUE050390T2 (hu) * 2013-01-29 2020-11-30 Max Delbrueck Centrum Fuer Molekulare Medizin Mdc MAGE-A 1-t felismerõ nagy aviditású kötõ molekulák
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자

Also Published As

Publication number Publication date
NZ731571A (en) 2022-02-25
CA2963332A1 (en) 2016-04-14
KR20170092535A (ko) 2017-08-11
SG11201701983WA (en) 2017-04-27
WO2016055785A1 (en) 2016-04-14
US11203627B2 (en) 2021-12-21
ZA201701823B (en) 2019-06-26
IL251524B (en) 2021-09-30
RU2017115932A3 (enExample) 2019-04-05
BR112017007202A2 (pt) 2018-03-06
RU2017115932A (ru) 2018-11-12
CN107001443A (zh) 2017-08-01
JP2020127406A (ja) 2020-08-27
AU2015329783A1 (en) 2017-05-25
MX2017004559A (es) 2018-02-23
JP2017533698A (ja) 2017-11-16
US20180208638A9 (en) 2018-07-26
US20170218043A1 (en) 2017-08-03
JP6751391B2 (ja) 2020-09-02
IL251524A0 (en) 2017-05-29
AU2020203201A1 (en) 2020-06-04
EP3204409A1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
IL262144A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
ZA201701823B (en) T cell receptors
IL252258B (en) K-R-EST anti-mutation cell receptors
GB201522592D0 (en) T cell receptors
SMT202300448T1 (it) Recettori di cellule t
HUE042287T2 (hu) Lítium-kén cella
GB201518991D0 (en) T cell receptors
HK1238270A1 (en) T cell receptors
GB201410934D0 (en) T cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)